Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance

BridgeBio Pharma IncTrade
Direxion Daily S&P 500 Bull 3X SharesTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? BridgeBio Pharma Inc trades at $84.61 (market cap $16.36B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.64. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.

BBIOSPXL
Market Cap
$16.36B
Sector
HealthLeveraged / Inverse
52-Week High
$90.17$296.39
52-Week Low
$47.29$170.20
Enterprise Value
$18.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Direxion Daily S&P 500 Bull 3X Shares

SPXL trades at $295.71, down 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength while RSI levels suggest potential overbought conditions. Recent news highlights S&P 500 reaching record highs with JPMorgan raising its 2026 target to 8,000, citing AI-driven earnings strength and corporate performance.

The leveraged ETF benefits from strong market momentum but faces valuation concerns with the S&P 500 at historically high Shiller P/E ratios. Key risks include market volatility ahead of inflation reports and potential profit-taking near resistance levels. The AI investment theme provides growth catalysts, though elevated valuations warrant caution for new positions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Direxion Daily S&P 500 Bull 3X Shares

SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.

Read more on SPXL